President & CEO
Mr. DiPasquale has a strong history of executive leadership success within the life sciences industry. Prior to joining Orgenesis, Mr. DiPasquale worked with GlaxoSmithKline Inc. ("GSK"), a world leading research-based pharmaceutical company, for over 16 years in Canada. There, he served in various technology and marketing capacities including his most recent role as Vice President, Business Development and Corporate Planning. Among his many accomplishments at GSK, Mr. DiPasquale established and managed a multi-million dollar business unit focused on Type1 diabetes. He also led the creation, launch and management of a $50M GSK venture capital fund in Canada purposed with helping to commercialize Canadian scientific innovation from start-up and emerging life sciences companies. Mr. DiPasquale holds a B.Sc. in computer science from the University of Toronto and has completed the Executive Program at the Schulich School of Business.
Jacob BenArie MBA, B.Sc.
CEO, Orgenesis Ltd.
Prior his joining to Orgenesis, Jacob served for the last 5 years as the CEO of Beta-Stim Ltd, a privately held company that developed a therapy for the treatment of type 2 diabetics. Jacob also co-founded Beta-Stim, Slender Medical and the Medical Device Design & Manufacture Israel conference. Jacob has over 15 years of experience in different management and R&D positions in life science start–up companies. Mr. BenArie holds a B.Sc. in electronic engineering and MBA, both from the Technion - Israel Institute of Technology
Sarah Ferber Ph.D.
Chief Science Officer & Founder
Prof. Sarah Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aaron Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a post-doctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Prof. Ferber's breakthrough discovery suggested that humans carry their own 'stem-cells' throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferber’s lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber’s research work has been funded over the past 10 years by the Juvenile Diabetes Research Foundation (JDRF), the Israel Academy of Science foundation (ISF) and D-Cure, a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, over US$4M)
Dov Weinberg CPA, MBA
Mr. Dov Weinberg has more than 11 years of experience in the medical device area. He is an owner and president of Weinberg Dalyo Inc. a U.S corporation which renders business development and financial services to companies in the life science industry. Serves currently as CFO of QRS systems Inc. Innovate Inc. and NaNaMEd LLC and was the Chief Financial officer of Impulse Dynamics from December 2000 until the beginning of 2009. Prior to that Mr. Weinberg served for more than 15 years as the CFO of a large industrial multinational public corporation in charge of finance, information systems, and taxation of the company and its worldwide subsidiaries. Mr. Weinberg has been a Certified Public Account since 1979 and received an MBA from Bar-Ilan University in 1984 and a B.A. in Economics & Accounting from Tel Aviv University in 1977.